Pavan Reddy, MD
Year elected: 2009
Current membership category: Active
Moshe Talpaz Professor of Oncology
University of Michigan
1500 E. Medical Center Drive, SPC 5932
7215 Cancer Center
Ann Arbor, MI 48109-5948
United States of America
Phone: 734-764-2248
Facsimile: 734-647-9647
Email: reddypr@umich.edu

Biographical statement

Dr. Reddy’s research interest is to understand the biological mechanisms and to improve the clinical application of allogeneic hematopoietic cell transplantation (HCT). His lab focuses on immunobiology of acute graft-versus-host disease (GVHD) and the graft-versus-leukemia (GVL) responses, the major complication and beneficial effect, respectively, of allogeneic HCT. Dr. Reddy’s laboratory aims to characterize the molecular and cellular interactions that are critical for GVHD and GVL. Specifically, he is focused on investigating the role of direct antigen presentation by GVHD target / tumor cells or cross-presentation on host /donor derived antigen presenting cells (APCs). Dr. Reddy’s laboratory made the seminal discovery about the absolute requirement for antigen presenting cells and for the tumor expression of allo-antigens in mediating GVL. His lab has recently discovered a novel biochemical pathway, acetylation of STAT proteins, can regulate the function of dendritic cells. His laboratory is now building on these crucial discoveries by taking a combination of both broad based discovery and reductionistic approaches to further elucidate the cellular and molecular mechanisms. Another important line of work in Dr. Reddy’s laboratory is to apply the insights gained from understanding the basic biology of GVH responses into the development of novel immuno-modulatory approaches that can be translated into clinical HCT. Dr. Reddy’s group demonstrated that histone deacetylase (HDAC) inhibitors regulate the function of antigen presenting cells / T cells and thus modulate GVHD and GVL. An exciting outcome of this work has been the development of a clinical protocol to directly test deacetylase inhibitors as novel adjunct therapy for prevention of clinical GVHD in a proof of principle clinical trial by Dr. Reddy and his colleagues. His research is supported by multiple grants from NIH and foundations.

Institutional affiliations

University of Michigan Medical School (Primary)
Elizabeth K. Speliotes, MD, PhD, MPH is the representative at this institution.

Specialties

Internal Medicine

Positions held

Co-Director
Scientific Director